炎症性肠病合并非酒精性脂肪性肝病的经济负担及危险因素

冯巩; 弥曼; 李雪萍; 贺娜; 陈子君; 牛春燕

doi:10.3969/j.issn.1001-5256.2018.12.042

炎症性肠病合并非酒精性脂肪性肝病的经济负担及危险因素

DOI: 10.3969/j.issn.1001-5256.2018.12.042

1. 西安医学院
2. 西安医学院第一附属医院
3. 华中科技大学附属协和医院
4. 厦门大学附属翔安医院消化内科

基金项目:

陕西省科技攻关计划(2016SF-327)；陕西省普通高等学校优势学科建设项目(陕教位[2014]3号)；

详细信息

中图分类号: R575.5;R574
计量
- 文章访问数: 1625
- HTML全文浏览量: 23
- PDF下载量: 320
- 被引次数: 0
出版历程
- 出版日期: 2018-12-20

The economic burden and risk factors in inflammatory bowel disease with nonalcoholic fatty liver disease

Research funding:

摘要

摘要: 非酒精性脂肪性肝病(NAFLD)是一种影响约1/4普通人群的疾病,已成为我国及西方国家第一大慢性肝病,造成了巨大的医疗和经济负担。炎症性肠病(IBD)患者中,NAFLD的患病率估计高达40%,包括溃疡性结肠炎和克罗恩病。主要介绍IBD患者中合并NAFLD的现状与经济负担、危险因素评估,并对该类疾病进行总结与展望,以期为未来该领域的进一步研究奠定基础。
- 脂肪肝 /
- 炎症性肠病 /
- 危险因素 /
- 综述
Abstract: Nonalcoholic fatty liver disease (NAFLD) is a disease affecting about a quarter of the general population and has become the most important chronic liver disease in China and Western countries, causing huge medical and economic burdens. The prevalence rate of NAFLD is estimated to be as high as 40% in patients with inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease. This article mainly introduces the current status, economic burden, and risk factors for NAFLD in IBD patients and summarizes the current status and prospects of such diseases, in order to lay a foundation for further research in this field.
- fatty liver /
- inflammatory bowel disease /
- risk factors /
- review

HTML全文

参考文献(49)

[1] FENG G, HAN HJ, QI X, et al. Establishment of a noninvasive diagnosis quation for nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2018, 34 (6) :1264-1267. (in Chinese) 冯巩, 韩海静, 齐雪, 等.非酒精性脂肪性肝病无创性诊断方程的构建[J].临床肝胆病杂志, 2018, 34 (6) :1264-1267.

[2] BARGIGGIA S, MACONI G, ELLI M, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease:Study of 511 subjects at a single center[J]. J Clin Gastroenterol, 2003, 36 (5) :417-420.

[3] ROCCHI A, BENCHIMOL EI, BERNSTEIN CN, et al. Inflammatory bowel disease:A Canadian burden of illness review[J]. Can J Gastroenterol, 2012, 26 (11) :811-817.

[4] AHMED A, WONG RJ, HARRISON SA. Nonalcoholic fatty liver disease review:Diagnosis, treatment, and outcomes[J]. Clin Gastroenterol Hepatol, 2015, 13 (12) :2062-2070.

[5] CAPPELLO M, RANDAZZO C, BRAVATI, et al. Liver function test abnormalities in patients with inflammatory bowel diseases:A hospital-based survey[J]. Clin Med Insights Gastroenterol, 2014, 7:25-31.

[6] THIN L WY, LAWRANCE IC, SPILSBURY K, et al. Detection of liver injury in IBD using transient elastography[J]. J Crohns Colitis, 2014, 8 (7) :671-677.

[7] VERMA S, JENSEN D, HART J, et al. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD) [J]. Liver Int, 2013, 33 (9) :1398-1405.

[8] CHANDRASHEKARAN V, SETH RK, DATTAROY D, et al.HMGB1-RAGE pathway drives peroxynitrite signaling-induced IBD-like inflammation in murine nonalcoholic fatty liver disease[J]. Redox Biol, 2017, 13:8-19.

[9] BESSISSOW T, LE NH, ROLLET K, et al. Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease[J]. Inflamm Bowel Dis, 2016, 22 (8) :1937-1944.

[10] SOURIANARAYANANE A, GARG G, SMITH TH, et al. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease[J]. J Crohns Colitis, 2013, 7 (8) :e279-e285.

[11] BOSCH DUSTIN E, YEH MATTHEW M. Primary sclerosing cholangitis is protective against nonalcoholic fatty liver disease in inflammatory bowel disease[J]. Hum Pathol, 2017, 69:55-62.

[12] CHAO CY, BATTAT R, AL KHOURY A, et al. Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease:A review article[J]. World J Gastroenterol, 2016, 22 (34) :7727-7734.

[13] NIRIELLA MA, DE SILVA ST, KASTURIRATNA A, et al. Lean non-alcoholic fatty liver disease (Lean-NAFLD) :Characteristics and risk factors from a community cohort follow up study[C]//Sri Lanka Medical Association, 2016.

[14] WIEST R, ALBILLOS A, TRAUNER M, et al. Targeting the gutliver axis in liver disease[J]. J Hepatol, 2017, 67 (5) :1084-1103.

[15] TILG H, CANI PD, MAYER EA. Gut microbiome and liver diseases[J]. Gut, 2016, 65 (12) :2035.

[16] BOURSIER J, MUELLER O, BARRET M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota[J]. Hepatology, 2016, 63 (3) :764-775.

[17] LLOPIS M, CASSARD AM, WRZOSEK L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease[J]. Gut, 2016, 65 (5) :830-839.

[18] SABINO J, VIEIRA-SILVA S, MACHIELS K, et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD[J]. Gut, 2016, 65 (10) :1681-1690.

[19] LACHAR J, BAJAJ JS. Changes in the microbiome in cirrhosis and relationship to complications:Hepatic encephalopathy, spontaneous bacterial peritonitis, and sepsis[J]. Semin Liver Dis, 2016, 36 (4) :327-330.

[20] BAJAJ JS, FAGAN A, SIKAROODI M, et al. Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis[J]. Liver Transpl, 2017, 23 (7) :907-914.

[21] CANI PD, AMAR J, IGLESIAS MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance[J]. Diabetes, 2007, 56 (7) :1761-1772.

[22] SPADONI L, ZAGATO E, BERTOCCHI A, et al. A gut-vascular barrier controls the systemic dissemination of bacteria[J]. Science, 2015, 350 (6262) :830-834.

[23] YILMAZ Y. Review article:Is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?[J]. Aliment Pharmacol Ther, 2012, 36 (9) :815-823.

[24] SMYTHIES LE, WAITES KB, LINDSEY JR, et al. Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-gamma, gene-deficient mice[J]. J Immunol, 2000, 165 (2) :1022-1029.

[25] RESTELLINI S, CHAZOUILLRES O, FROSSARD JL. Hepatic manifestations of inflammatory bowel diseases[J]. Liver Int, 2017, 37 (4) :475-489.

[26] GANZETTI G, CAMPANATI A, OFFIDANI A. Non-alcoholic fatty liver disease and psoriasis:So far, so near[J]. World J Hepatol, 2015, 7 (3) :315-326.

[27] LU C. Study on the influence of inflammatory bowel disease on hepatic fat changes[D]. Zhejiang:Zhejiang Univ, 2016. (in Chinese) 陆超.炎症性肠病对肝脏脂变影响的研究[D].浙江:浙江大学, 2016.

[28] MIKOLASEVIC I, LUKENDA V, RACKI S, et al. Nonalcoholic fatty liver disease (NAFLD) -a new factor that interplays between inflammation, malnutrition, and atherosclerosis in elderly hemodialysis patients[J]. Clin Interv Aging, 2014, 9:1295-1303.

[29] SANADA Y, URAHASHI T, WAKIYA T, et al. Non-alcoholic steatohepatitis caused by malnutrition after pediatric liver transplantation[J]. Pediatr Int, 2011, 53 (6) :1077-1081.

[30] FAN JG, LI F, CAI XB, et al. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders[J]. J Gastroenterol Hepatol, 2007, 22 (7) :1086-1091.

[31] ANGELICO M, DELLA GUARDIA P. Review article:Hepatobiliary complications associated with total parenteral nutrition[J]. Aliment Pharmacol Ther, 2000, 14 (Suppl 2) :54-57.

[32] HOWARD LYN, ASHLEY C. Management of complications in patients receiving home parenteral nutrition[J]. Gastroenterology, 2003, 124 (6) :1651-1661.

[33] BESSISSOW T, l E NH, ROLLET K, et al. Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease[J]. Inflamm Bowel Dis, 2016, 22 (8) :1937-1944.

[34] SOURIANARAYANANE A, GARG G, SMITH TH, et al. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease[J]. J Crohns Colitis, 2013, 7 (8) :279-285.

[35] NAGAHORI M, HYUN SB, TOTSUKA T, et al. Prevalence of metabolic syndrome is comparable between inflammatory bowel disease patients and the general population[J]. J Gastroenterol, 2010, 45 (10) :1008-1013.

[36] YORULMAZ E, ADALI G, YORULMAZ H, et al. Metabolic syndrome frequency in inflammatory bowel diseases[J]. Saudi J Gastroenterol, 2011, 17 (6) :376-382.

[37] DOLINSKY VW, DOUGLAS DN, LEHNER R, et al. Regulation of the enzymes of hepatic microsomal triacylglycerol lipolysis and re-esterification by the glucocorticoid dexamethasone[J]. Biochem J, 2004, 378 (3) :967-974.

[38] D'SOUZA AM, BEAUDRY JL, SZIGIATO AA, et al. Consumption of a high-fat diet rapidly exacerbates the development of fatty liver disease that occurs with chronically elevated glucocorticoids[J]. Am J Physiol Gastrointest Liver Physiol, 2012, 302 (8) :850-863.

[39] HUBEL JM, SCHMIDT SA, MASON RA, et al. Influence of plasma cortisol and other laboratory parameters on nonalcoholic fatty liver disease[J]. Horm Metab Res, 2015, 47 (7) :479-484.

[40] LAPUMNUAYPOL K, KANJANAHATTAKIJ N, PISARCIK D, et al. Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease:A meta-analysis[J]. Eur J Gastroenterol Hepatol, 2018, 30 (8) :854-860.

[41] LIU TC, STAPPENBECK TS. Genetics and pathogenesis of inflammatory bowel disease[J]. Annu Rev Pathol, 2016, 11:127-148.

[42] DIGNASS A, VAN ASSCHE G, LINDSAY JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease:Current management[J]. J Crohns Colitis, 2010, 4 (1) :28-62.

[43] BATH ROOPJEET K, BRAR NAVKIRAN K, FOROUHAR FARIPOUR A, et al. A review of methotrexate-associated hepatotoxicity[J]. J Dig Dis, 2014, 15 (10) :517-524.

[44] SAKTHISWARY R, CHAN GY, KOH ET, et al. Methotrexateassociated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis[J]. Scientific World J, 2014, 2014:823763.

[45] RUIZ AG, CASAFONT F, CRESPO J, et al. Lipopolysaccharidebinding protein plasma levels and liver TNF-alpha gene expression in obese patients:Evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis[J]. Obes Surg, 2007, 17 (10) :1374-1380.

[46] BARBUIO R, MILANSKI M, BERTOLO MB, et al. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet[J]. J Endocrinol, 2007, 194 (3) :539-550.

[47] KOCA SS, BAHCECIOGLU IH, POYRAZOGLU OK, et al. The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine-and cholinedeficient diet[J]. Inflammation, 2008, 31 (2) :91-98.

[48] YALCIN M, AKARSU M, CELIK A, et al. A comparison of the effects of infliximab, adalimumab, and pentoxifylline on rats with non-alcoholic steatohepatitis[J]. Turk J Gastroenterol, 2014, 25 (Suppl 1) :167-175.

[49] ADAMS LA, ZEIN CO, ANGULO P, et al. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis[J]. Am J Gastroenterol, 2004, 99 (12) :2365-2368.

施引文献

资源附件(0)

访问统计